Seelos Therapeutics, Inc.

Seelos Therapeutics was a clinical-stage biopharmaceutical company based in New York, focused on CNS disorders and rare diseases. Pipeline included SLS-002 (intranasal ketamine for MDD) and SLS-005 (IV trehalose for ALS and Huntington's). Assets acquired by GLD Partners in October 2025 following Chapter 11 bankruptcy.